Telomere biology for non-biologists: what shortening actually means for ageing

Open any longevity article and the word telomere shows up. There is a clean version of what a telomere is, and a messy version of what its length actually means for human ageing. The two do not always meet in the marketing.

This is the clean version — and the place where the messy version has to be honest about itself.

What a telomere actually is

Inside every cell are chromosomes — long, tightly packed strings of DNA. The instructions a cell needs to do its job are written along those strings. At each end of every chromosome, sitting like a buffer between the working DNA and the cellular machinery that handles it, is a stretch of repetitive, non-coding sequence. In humans, that sequence is TTAGGG, repeated thousands of times. That stretch is a telomere.

The job of the telomere is not to carry information. The job is to protect the end of the chromosome from being treated like damage. The cell has a whole repair apparatus dedicated to fixing broken DNA, and without a telomere, that apparatus would mistake every chromosome end for a break, try to fuse them, and break the genome doing it. The telomere is the part the repair machinery is told to leave alone.

Why they shorten

Every time a cell divides, it has to copy its entire genome — including the telomeres. The copying machinery has a quirk that has been called the end-replication problem: it cannot quite reach the very last few nucleotides at one end of a strand. Each round of division shaves a small amount off the telomere.

A young cell starts with long telomeres. After roughly fifty divisions in culture, the telomeres get short enough that the cell stops dividing — a state called replicative senescence, first described by Leonard Hayflick in 1961 and often referred to as the Hayflick limit. The cell does not die. It stops dividing.

That is the biology behind one of the load-bearing claims in popular longevity coverage: cells have a built-in division counter, the counter is telomere length, and once it runs out, the body’s regenerative tissues start to wear down.

Telomerase, and the safety question that comes with it

Some cells need to divide many more than fifty times. Stem cells. The cells that produce sperm and eggs. Immune cells responding to infection. Those cells express an enzyme — telomerase — that adds the repetitive TTAGGG sequence back onto telomere ends, undoing the shortening. Most adult cells switch this enzyme off. Stem cells keep it on, at low levels. Sperm and egg progenitors run it at high levels. The body uses it carefully.

Most cancer cells — somewhere around 85 to 90 percent in published surveys — re-activate telomerase. That is one of the things that makes a tumour cell different from a normal one. A cancer cell with no telomerase would run out of telomere and stop. A cancer cell with telomerase keeps dividing indefinitely. This is the structural reason every anti-ageing intervention based on inducing telomerase has to answer a cancer-safety question: the same enzyme is what malignant cells use to scale.

What the population data actually shows

Population-level observational data is consistent: average telomere length in peripheral blood cells declines with age, and people with shorter telomeres at a given chronological age have, on average, slightly higher all-cause mortality and slightly higher rates of age-related disease.

That is a correlation. The harder claim — that telomere shortening causes ageing, rather than reflecting it — has been tested with the cleanest tool epidemiology has, Mendelian randomization. Genetic variants that affect telomere length are used as natural experiments, asking whether people who inherited longer telomeres live longer, healthier lives. The published evidence is mixed. There is signal in some directions (longer telomeres associate with lower risk of some diseases) and not others (no straightforward longer-telomere–longer-lifespan effect). The picture that emerges is less telomeres cause ageing and more telomere length is one of several markers of how cells have been treated over a lifetime.

That distinction matters for any product sold on the premise that lengthening a telomere lengthens a life. The premise rests on a causal claim the human data does not yet support.

Epitalon: the peptide attached to this story

Most of the consumer-facing telomere story in peptide marketing points at one molecule. Epitalon — also written epithalon — is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from a bovine pineal extract called epithalamin and characterised since the 1990s by Vladimir Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology.

The 2003 Khavinson paper in Bull Exp Biol Med is the foundational mechanism paper for the longevity claim. In human somatic cells in culture, epitalon induced telomerase activity and telomere elongation. That is the result the entire anti-ageing marketing case rests on. It is a real published finding in a real journal.

It is also what it is. The cells were in a dish. The result has not been replicated in cells in vivo in a human. The transfer from telomerase induction in cultured cells to measurably slower ageing in adults is the part of the story the published evidence does not span.

The 2001 Anisimov paper — the foundational animal lifespan study from the same Russian research tradition — reported that epitalon influenced biological-age parameters and lifespan in mice. Russian-language publication, original animal data, foundational for the lifespan claim. Mice are not humans. The path between mouse lifespan extension and human lifespan extension is the path almost every candidate longevity intervention fails to complete; the molecules that survive it are the ones with controlled human trials, and epitalon does not have one.

The 2015 Vanhee analytical paper in Drug Testing and Analysis gives a sense of where the peptide actually circulates: Belgian regulators identified epitalon among the active compounds in illegal pharmaceutical preparations seized in the field, alongside other unlicensed compounds marketed for cancer, ageing, and retinitis pigmentosa. The supply side has been ahead of the evidence base for at least a decade.

The 2026 Mavrych review in Frontiers in Aging places epitalon in the longevity-peptide cluster and frames the central honest point: this is a non-approved peptide with limited human-trial evidence, sitting alongside other peptides with the same evidence shape.

The regulatory positioning is the part nobody quotes

Epitalon is on the July 24, 2026 FDA Pharmacy Compounding Advisory Committee docket per Federal Register notice 2026-07361 — both free-base and acetate forms — evaluated for insomnia, grouped with Emideltide (DSIP) and Semax.

Read that twice. The FDA is reviewing whether US-licensed pharmacies should be allowed to compound epitalon, on a doctor’s prescription, for insomnia. Not anti-ageing. Not telomere lengthening. Not longevity. The indication the agency is willing to evaluate is the one with some Russian-tradition sleep-architecture support; the indication the supplement market sells under is not the indication on review. We covered how PCAC reviews actually work in What is the PCAC.

The three sentences that summarise the file

The telomere biology is real. The lifespan claim from telomere-targeted peptide dosing is not supported by any controlled human trial. The FDA review now scheduled for epitalon is for insomnia.

Wolverine Health is the version of this conversation where a doctor reads that file with you, against an indication the FDA has actually reviewed, dispensing through a US-licensed compounding pharmacy. Join the waitlist for a note the day a controlled adult-human telomere trial reads out — or the day the post-PCAC rulemaking on epitalon-for-insomnia lands.